Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- European shares subdued as surging crude sharpens focus on ECB rate path
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) PT Raised to $89 at RBC Capital
February 15, 2019 7:16 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $89.00 (from $81.00) while maintaining a Outperform rating.
The analyst commented, "Coming off of a solid quarter for sales and guidance, we see the potential for some additional appreciation in INCYwith... More
Incyte (INCY) PT Raised to $100 at Raymond James
February 15, 2019 7:10 AM ESTRaymond James analyst Reni Benjamin raised the price target on Incyte (NASDAQ: INCY) to $100.00 (from $85.00) while maintaining a Strong Buy rating following results and guidance.
Benjamin said key takeaways include: 1) The Jakafi franchise remains solid with 2018 sales at $1.39 billion; 2) 2019 guidance is for Jakafi to... More
Incyte (INCY) Misses Q4 EPS by 7c
February 14, 2019 7:04 AM ESTIncyte (NASDAQ: INCY) reported Q4 EPS of $0.40, $0.07 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $468 million versus the consensus estimate of $485.8 million.
2019 Financial... More
